BIIBのPER（株価収益率）は？

BIOGEN INC（BIIB）は現在PER 34.77倍で取引されています。

BIIBのROE（自己資本利益率）は？

BIOGEN INCのROEは4.43%です。

BIIBの配当利回りは？

BIOGEN INCの配当利回りは0.00%です。

BIIBの品質スコア（Quality Score）は？

当社のAIはBIIBの総合財務品質を100点中46点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。

BIIBは今が買い時ですか？

当社AIのタイミングスコアは100点中91点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。

BIIBはどのセクターに属しますか？

BIOGEN INCはHealthcare >> Drug Manufacturers - Generalセクターに分類されます（NASDAQ市場）

BIIB (NASDAQ) 株価分析 | BIOGEN INC

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-06-30)

BIIB AI Analysis Summary

Our AI summary for BIIB: BIOGEN INC (NASDAQ), Healthcare >> Drug Manufacturers - General sector. The stock currently trades at a P/E of 34.77, ROE of 4.43%, a dividend yield of 0.00%. Its financial Quality Score stands at 46/100 — fundamentals below the market average. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

BIIB

BIOGEN INC

US:NASDAQ STOCK Healthcare >> Drug Manufacturers - General

USD 202.95

-4.98 (-2.40%) Day Change

Watchlist Portfolio Compare Chart

34.77

P/E

0.43

D/E

4.4%

ROE

2.6%

ROA

0.00%

Div Yield

BIOGEN INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 202.95 Price -4.98 (-2.40%) Day Change	NEWS SCORE: N/A

BIIB, ファンダメンタルスコアはnot good ( ファンダメンタル = 46) but テクニカルスコアは ...(Sign In to See)...

Loading chart...

46 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROEが低い
ROEの伸びが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
ROAの伸びが低い
NPMが低い
NPMの伸びが低い

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not quite good , and ability to make profit is ok , ...

Deepscope 分析

42%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	N/A
Magic Formula Rank by ROA	2219
Magic Formula Rank by ROE	2219
Magic Formula Rank by ROIC	2246
Price	202.95
PBV / Sector	1.63 / 2.68
Earning Per Share	5.52

PE / Sector	34.77 / 27.65
PEG or PE/Growth / Sector	N/A / 0.28
Average 1M Daily Value	287.96 M GREAT
Average 1W Daily Value	268.77 M GREAT

Timing Factors

71%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

58%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

ポイントになる統計

60%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	8.39 / 17.30
NPM Average (%) / Sector	16.04 / 17.60 GREAT
NPM Change Average (%) / Sector	-18.97 / 92.67
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	2.60 / 8.73
ROA Average (%) / Sector	5.91 / 8.56
ROA Change Average (%) / Sector	-23.97 / 94.23
ROE (%) / Sector	4.43 / 26.78
ROE Average (%) / Sector	10.37 / 13.05
ROE Change Average (%) / Sector	-26.49 / 96.64
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

配当

Dividend (%) / Sector	N/A / 2.40
Dividend Average (%) / Sector	N/A / 3.39
Dividend Change Average (%) / Sector	N/A / 4.92

登録情報

Analyze Date	2026-08-01 07:59:33
Symbol	BIIB
Name	BIOGEN INC
Sector	Healthcare >> Drug Manufacturers - General
Market	NASDAQ
Listed Shares	147.75 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	30,722.49 / 256,404.20

ニュース

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 225 Binney Street, Cambridge, MA, United States, 02142

Phone: 617 679 2000

Website: https://www.biogen.com

Employees: 7,500

Sector: Healthcare >> Drug Manufacturers - General

Description: Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.